Abstract
Background: Variation in care is a ubiquitous feature of medical practice and may lead to significant differences in health care costs, quality, and outcomes. We undertook this study to determine the extent of intercenter variation in the initial management of children newly diagnosed with Crohn's disease. Methods: We analyzed the utilization of 5 classes of medication (immunomodulators, prednisone, antibiotics, 5-aminosalicylates, and infliximab) among 311 children with newly diagnosed Crohn's disease followed at 10 North American pediatric gastroenterology centers. Multivariate logistic regression was used to compare the utilization rate of each class of medication at each of the 10 centers, adjusting for potential confounders including patient age, sex, race, disease severity, and anatomic location of disease. Results: Median utilization of each class of medication was: immunomodulators, 56% (range 29%-97%); prednisone, 78% (range 32%-88%); antibiotics, 29% (range 11%-68%); 5-aminosalicylates, 63.5% (range 18%-92%); and infliximab, 7.5% (range 3%-21%). Each of these treatments showed statistically significant intercenter variation in utilization (P < 0.001 for immunomodulators, prednisone, antibiotics, and 5-ASA; P = 0.02 for infliximab). After adjusting for the demographic and clinical factors listed above, intercenter variation remained significant; however, the low utilization of infliximab precluded multivariate analysis. Conclusions: Widespread intercenter variation in the medical management of newly diagnosed children with Crohn's disease was observed, even after adjusting for possible differences in case mix between institutions. This variation may lead to unintended differences in health care costs and outcomes.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 890-895 |
| Number of pages | 6 |
| Journal | Inflammatory bowel diseases |
| Volume | 13 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 1 2007 |
| Externally published | Yes |
Fingerprint
All Science Journal Classification (ASJC) codes
- Immunology and Allergy
- Gastroenterology
Cite this
}
Intercenter variation in initial management of children with Crohn's disease. / Kappelman, Michael D.; Bousvaros, Athos; Hyams, Jeffrey; Markowitz, James; Pfefferkorn, Marian; Kugathasan, Subra; Rosh, Joel; Otley, Anthony; Mack, David; Griffiths, Anne; Evans, Jonathan; Grand, Richard; Langton, Christine; Kleinman, Ken; Finkelstein, Jonathan A.
In: Inflammatory bowel diseases, Vol. 13, No. 7, 01.07.2007, p. 890-895.Research output: Contribution to journal › Article
TY - JOUR
T1 - Intercenter variation in initial management of children with Crohn's disease
AU - Kappelman, Michael D.
AU - Bousvaros, Athos
AU - Hyams, Jeffrey
AU - Markowitz, James
AU - Pfefferkorn, Marian
AU - Kugathasan, Subra
AU - Rosh, Joel
AU - Otley, Anthony
AU - Mack, David
AU - Griffiths, Anne
AU - Evans, Jonathan
AU - Grand, Richard
AU - Langton, Christine
AU - Kleinman, Ken
AU - Finkelstein, Jonathan A.
PY - 2007/7/1
Y1 - 2007/7/1
N2 - Background: Variation in care is a ubiquitous feature of medical practice and may lead to significant differences in health care costs, quality, and outcomes. We undertook this study to determine the extent of intercenter variation in the initial management of children newly diagnosed with Crohn's disease. Methods: We analyzed the utilization of 5 classes of medication (immunomodulators, prednisone, antibiotics, 5-aminosalicylates, and infliximab) among 311 children with newly diagnosed Crohn's disease followed at 10 North American pediatric gastroenterology centers. Multivariate logistic regression was used to compare the utilization rate of each class of medication at each of the 10 centers, adjusting for potential confounders including patient age, sex, race, disease severity, and anatomic location of disease. Results: Median utilization of each class of medication was: immunomodulators, 56% (range 29%-97%); prednisone, 78% (range 32%-88%); antibiotics, 29% (range 11%-68%); 5-aminosalicylates, 63.5% (range 18%-92%); and infliximab, 7.5% (range 3%-21%). Each of these treatments showed statistically significant intercenter variation in utilization (P < 0.001 for immunomodulators, prednisone, antibiotics, and 5-ASA; P = 0.02 for infliximab). After adjusting for the demographic and clinical factors listed above, intercenter variation remained significant; however, the low utilization of infliximab precluded multivariate analysis. Conclusions: Widespread intercenter variation in the medical management of newly diagnosed children with Crohn's disease was observed, even after adjusting for possible differences in case mix between institutions. This variation may lead to unintended differences in health care costs and outcomes.
AB - Background: Variation in care is a ubiquitous feature of medical practice and may lead to significant differences in health care costs, quality, and outcomes. We undertook this study to determine the extent of intercenter variation in the initial management of children newly diagnosed with Crohn's disease. Methods: We analyzed the utilization of 5 classes of medication (immunomodulators, prednisone, antibiotics, 5-aminosalicylates, and infliximab) among 311 children with newly diagnosed Crohn's disease followed at 10 North American pediatric gastroenterology centers. Multivariate logistic regression was used to compare the utilization rate of each class of medication at each of the 10 centers, adjusting for potential confounders including patient age, sex, race, disease severity, and anatomic location of disease. Results: Median utilization of each class of medication was: immunomodulators, 56% (range 29%-97%); prednisone, 78% (range 32%-88%); antibiotics, 29% (range 11%-68%); 5-aminosalicylates, 63.5% (range 18%-92%); and infliximab, 7.5% (range 3%-21%). Each of these treatments showed statistically significant intercenter variation in utilization (P < 0.001 for immunomodulators, prednisone, antibiotics, and 5-ASA; P = 0.02 for infliximab). After adjusting for the demographic and clinical factors listed above, intercenter variation remained significant; however, the low utilization of infliximab precluded multivariate analysis. Conclusions: Widespread intercenter variation in the medical management of newly diagnosed children with Crohn's disease was observed, even after adjusting for possible differences in case mix between institutions. This variation may lead to unintended differences in health care costs and outcomes.
UR - http://www.scopus.com/inward/record.url?scp=34547616791&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34547616791&partnerID=8YFLogxK
U2 - 10.1002/ibd.20121
DO - 10.1002/ibd.20121
M3 - Article
C2 - 17286275
AN - SCOPUS:34547616791
VL - 13
SP - 890
EP - 895
JO - Inflammatory Bowel Diseases
JF - Inflammatory Bowel Diseases
SN - 1078-0998
IS - 7
ER -